Evaluated doses of YUTREPIA™ (treprostinil) inhalation powder from 26.5 mcg to 212 mcg which are comparable to 3 to 24 breaths of nebulized Tyvaso ® per session Achieved therapeutic levels by Month 2 and continued to titrate to higher levels for approximately one year on average before rolling into

MORRISVILLE, N.C. , Aug. 01, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will be participating at the following investor conferences next week: BTIG Biotechnology Conference 2022 Date: Monday, August 8, 2022 Location: Hybrid Event at St.

MORRISVILLE, N.C. , July 21, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced that, in connection with the previously announced appointment of Rajeev Saggar , M.D., Liquidia’s new Chief Medical Officer, it has agreed to grant him an employment inducement equity award.

MORRISVILLE, N.C. , July 19, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Patent Trial and Appeal Board (PTAB) ruled in its favor in the Inter Partes Review (IPR) proceeding against U.S. Patent No. 10,716,793 (‘793 patent) owned by United Therapeutics

MORRISVILLE, N.C. , June 27, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the company was added as a member of the US small-cap Russell 2000® Index, effective after the US market opens on June 27 , as part of the 2022 Russell indexes reconstitution.

MORRISVILLE, N.C. , June 24, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced the grant of inducement stock options exercisable for an aggregate of 24,800 shares of Liquidia’s common stock to newly hired non-executive employees under the Liquidia Corporation 2022

MORRISVILLE, N.C. , June 24, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced the grant of an inducement stock option exercisable for 2,000 shares of Liquidia’s common stock to a newly hired non-executive employee under the Liquidia Corporation 2022 Inducement Plan (the

MORRISVILLE, N.C. , June 20, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the appointment of Rajeev Saggar , M.D., to the position of Chief Medical Officer. In this role, Dr. Saggar will oversee all aspects of research, clinical

MORRISVILLE, N.C. , June 09, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the presentation of data related to the investigational use of YUTREPIA™ (treprostinil) inhalation powder, previously referred to as LIQ861, at the Pulmonary

MORRISVILLE, N.C. , June 07, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today an update to the company’s participation in the Jefferies Healthcare Conference . Mr. Michael Kaseta , Chief Financial Officer, will participate in a fireside chat on Thursday, June 9, 2022 ,